Approvals/TGA/KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial

Approved

STANDARD

KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial

Eli Lilly Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 1f3c97cfa4e46614
Product Name: KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial
Artg Id: 420194
Artg Name: KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial
Sponsor: Eli Lilly Australia Pty Ltd
Company Detail Path: /organization/eli-lilly-australia-pty-ltd
Artg Date: 2025-05-21
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/fa44688f3754998b07f43400de32c88e.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/dde2596be8e0c9bbbef01b7818c3cf4c.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

1f3c97cfa4e46614

Type

Standard